NICOX SA: management transactions · France · AMF

About NICOX SA

Nicox SA is a French biopharmaceutical company focused on ophthalmology. Founded in 1996 and historically based in Sophia Antipolis, France, the company was built around expertise in eye diseases and the development of innovative solutions designed to preserve vision and improve ocular health. Over time, Nicox evolved from a broader biotech profile into a more concentrated ophthalmology platform, combining research, clinical development, licensing partnerships, and the value creation of therapeutic assets. The company is currently listed on Euronext Growth Paris under ISIN FR0013018124, and is followed by investors specializing in healthcare and European biotech names. Nicox’s core portfolio is centered on ophthalmic programs at different stages of development. Its most advanced asset is NCX 470, a glaucoma candidate that has completed Phase 3 studies in the United States and China, while a separate Phase 3 program is ongoing in Japan. The company is also developing NCX 1728, a preclinical asset being evaluated for retinal conditions, as well as NCX 4251, a clinical-stage candidate for dry eye disease that has been exclusively licensed to a partner for the Chinese market. In parallel, Nicox already commercializes two products in the United States: VYZULTA for open-angle glaucoma and ZERVIATE for allergic conjunctivitis; ZERVIATE is also marketed in China. This mix of marketed products and late-stage pipeline assets is central to Nicox’s investment profile. Geographically, Nicox remains anchored in France while operating with an international footprint. The company maintains a base in Sophia Antipolis, a U.S. subsidiary in Durham, North Carolina, and relies on development and commercialization partnerships across Europe, the United States, and Asia, particularly China and Japan. Its business model is heavily partnership-driven, which reduces the need for a large direct commercial infrastructure while allowing the company to monetize clinical assets through licensing and collaboration agreements. Nicox’s focus on ophthalmology, a specialty therapeutic area with high scientific and regulatory barriers, gives it a distinctive positioning among listed French biotech companies. A notable feature of the group is its strategic emphasis in recent years on ophthalmology concentration, pipeline monetization, and disciplined capital allocation through industrial partnerships.